Membrane adenylyl cyclases (mACs) play an important role in signal transduction and are therefore potential drug targets. Earlier, we identified 2Ј,3Ј-O-(N-methylanthraniloyl) (MANT)-substituted purine nucleotides as a novel class of highly potent competitive mAC inhibitors (K i values in the 10 nM range). MANT nucleotides discriminate among various mAC isoforms through differential interactions with a binding pocket localized at the interface between the C1 and C2 domains of mAC. In this study, we examine the structure/activity relationships for 2Ј,3Ј-substituted nucleotides and compare the crystal structures of mAC catalytic domains (VC1:IIC2) bound to MANT-GTP, MANT-ATP, and 2Ј,3Ј-(2,4,6-trinitrophenyl) (TNP)-ATP. TNP-substituted purine and pyrimidine nucleotides inhibited VC1:IIC2 with moderately high potency (K i values in the 100 nM range). Elongation of the linker between the ribosyl group and the MANT group and substitution of N-adenine atoms with MANT reduces inhibitory potency. Crystal structures show that MANT-GTP, MANT-ATP, and TNP-ATP reside in the same binding pocket in the VC1:IIC2 protein complex, but there are substantial differences in interactions of base, fluorophore, and polyphosphate chain of the inhibitors with mAC. Fluorescence emission and resonance transfer spectra also reflect differences in the interaction between MANT-ATP and VC1:IIC2 relative to MANT-GTP. Our data are indicative of a three-site mAC pharmacophore; the 2Ј,3Ј-O-ribosyl substituent and the polyphosphate chain have the largest impact on inhibitor affinity and the nucleotide base has the least. The mAC binding site exhibits broad specificity, accommodating various bases and fluorescent groups at the 2Ј,3Ј-O-ribosyl position. These data should greatly facilitate the rational design of potent, isoformselective mAC inhibitors.
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Adenylyl cyclases (ACs) catalyze the conversion of ATP to cAMP, a ubiquitous cellular second messenger that regulates a variety of cellular processes including gene transcription, enzyme regulation, and sensory transduction in both prokaryotic and eukaryotic organisms (Sunahara et al., 1996; Hanoune and Defer, 2001 ). The nine isoforms of mammalian membrane AC (mAC) possess a pair of 2-fold symmetrically arranged class III cyclase homology domains in which catalysis occurs (Linder et al., 1990) . mAC isoforms are stimulated by the GTP-bound G protein G␣ s and, with the exception of type IX mAC, by the diterpene forskolin (FSK) (Sunahara et al., 1996) . The N-and C-terminal cyclase homology domains of mAC, when expressed as independent polypeptides and mixed together are catalytically competent and potently stimulated by FSK and G␣ s ⅐GTP␥S (Whisnant et al., 1996; Sunahara et al., 1997) . The three-dimensional structure of a catalytic heterodimer formed by the C1 domain of type V mAC and the C2 domain of type II mAC (VC1:IIC2), bound to FSK and G␣ s ⅐GTP␥S, has been described previously (Tesmer et al., 1997) , as have those of a variety of complexes in which VC1:IIC2 is bound to different ATP analogs (Tesmer et al., , 2000 . These crystal structures, together with biochemical data , indicate that ATP binds at one of two pseudosymmetric binding sites at the C1:C2 interface, whereas FSK binds to the pseudo-2-fold-related binding site (Tesmer et al., 1997) . The catalytic pocket includes a purine-binding subsite derived from the C2 domain that provides residues that specifically bind to the adenine base of the substrate. A second subsite, composed of residues derived from the ␤␣␤␤␣␤ motif of the C1 domain, includes a P-loop that accommodates the nucleotide phosphates and a pair of conserved aspartate residues that ligate the metal ion cofactors .
We have discovered that the fluorescent 2Ј(3Ј)-O-(Nmethylanthraniloyl) (MANT) derivative of GTP (MANT-GTP) is a highly potent competitive inhibitor of several mAC isoforms as well as of the soluble VC1:IIC2 complex (Gille and Seifert, 2003; Gille et al., 2004) . This finding was surprising in view of the high selectivity of mAC toward ATP in preference to GTP as a substrate (Sunahara et al., 1998; Gille et al., 2004) . The crystal structure of the VC1:IIC2 complex with MANT-GTP revealed that the MANT nucleotide is bound to the catalytic site in reverse orientation with respect to ATP analogs that are not derivatized with bulky substituents at the 2Ј(3Ј) position. In the reverse orientation, the guanine moiety in the purine binding site is accommodated by a pattern of hydrogen bonds analogous to those formed with adenine . The reverse orientation of MANT-GTP in the catalytic site is a consequence of the intercalation of the MANT moiety into a hydrophobic pocket at the interface between the C1 and C2 domains. Other MANT nucleotides, such as MANT-ATP, also inhibit G␣ s / FSK-activated VC1:IIC2 with K i values in the 10 to 100 nM range (Gille et al., 2004) . Thus, the catalytic site of mAC exhibits a much lower base specificity toward 2Ј(3Ј)-MANT nucleotides than was previously observed for other ATP analogs. The relaxation of specificity may arise from enlargement of the inhibitor-binding pocket as a result of the insertion of the MANT group into the interdomain site.
The forgoing findings prompted us to study in more detail the inhibition of VC1:IIC2 by 2Ј,3Ј-substituted purine and pyrimidine nucleotides. In particular, we examined MANT-EDA-ATP, which possesses a longer linker between the ribosyl moiety and the fluorophore, and three analogs (6-MANT-ATP, MABA-ATP, and MAHA-ATP) in which the fluorophore is attached to N6 and N8, respectively, of adenine through various linkers. We also examined 2Ј,3Ј-substituted TNP nucleotides, which are widely used for studying conformational changes in proteins (Hiratsuka, 2003) . Fluorescence analysis suggested that MANT-GTP and MANT-ATP bind to VC1:IIC2 in slightly different ways, calling for more detailed analysis by X-ray crystallography. In this study, we show that MANT-GTP, MANT-ATP, and TNP-ATP bind to a common site in mAC, but they do so in different ways, as corroborated by fluorescence spectroscopy. These data support the concept that the catalytic site of mAC, if structurally perturbed at the domain interface, shows broad specificity for active site-directed inhibitors. It may be inferred from our data that potent mAC inhibitors can be designed with considerable latitude with respect to the composition of the moieties that fill distinct subsites within the catalytic pocket of the enzyme.
Materials and Methods

Materials.
Recombinant adenylyl cyclase cytosolic C1a domain from canine type V (VC1), C2a domain from rat type II (IIC2), and bovine G␣ s were purified and stored as described previously (Tesmer et al., 2002) . G␣ s was activated by incubation with 10 M GTP␥S and 2 mM MgCl 2 at 30°C for 1 h, and the resulting G␣ s ⅐ GTP␥S complex was digested by trypsin. Free GTP␥S and inactivated G␣ s were removed by passing the sample through nickel-nitrilotriacetic acid resin. All MANT nucleotides, TNP-GDP, TNP-GTP, TNP-CTP, and TNP-UTP were obtained from Jena Bioscience (Jena, Germany). TNP-AMP, TNP-ADP, and TNP-ATP were obtained from Invitrogen (Eugene, OR). GTP␥S was from Roche (Indianapolis, IN). FSK and MP-FSK were obtained from Calbiochem (La Jolla, CA). Sources of other materials are described elsewhere (Gille and Seifert, 2003; Gille et al., 2004; Mou et al., 2005) .
AC Activity Assays. AC activity was determined essentially as described previously . In brief, reaction mixtures contained 40 M ATP/Mn 2ϩ , 10 mM MnCl 2 , and MANT nucleotides or TNP nucleotides at concentrations from 1 nM to 1 mM as appropriate to obtain saturated inhibition curves. In addition, assay tubes contained VC1 (8 nM) and IIC2 (40 nM). For experiments with G␣ s ⅐GTP␥S, tubes contained VC1 (3 nM), IIC2 (15 nM), and G␣ s ⅐GTP␥S (51 nM). Reactions were conducted in the presence of 100 M FSK. After a 2-min preincubation at 30°C, reactions were initiated by adding 20 l of reaction mixture containing (final) 1.0 Ci/tube [␣-32 P]ATP, 0.1 mM cAMP, and 100 mM KCl in 25 mM Na ϩ HEPES, pH 7.4. It should be noted that AC assays were conducted in the absence of an NTP-regenerating system to allow for the analysis of 2Ј,3Ј-substituted NDPs and NMPs that would otherwise be phosphorylated to the corresponding NTPs by the regenerating system (Gille et al., 2004) . Reactions were conducted for 10 to 20 min at 30°C and were terminated by the addition of 20 l of 2.2 N HCl. Denatured protein was sedimented by a 1-min centrifugation at 25°C and 15,000g. Sixty-five microliters of the supernatant fluid were applied onto disposable columns filled with 1. (Fisher, Pittsburgh, PA) . Competition isotherms were analyzed by nonlinear regression using the Prism 4.0 software (GraphPad, San Diego, CA).
Fluorescence Spectroscopy and Data Analysis. All experiments were conducted using a Cary Eclipse fluorescence spectrophotometer equipped with a Peltier-thermostated multicell holder at 25°C (Varian, Walnut Creek, CA). Measurements were performed in a quartz fluorescence microcuvette (Hellma, Plainview, NY). The final assay volume was 150 l. Reaction mixtures contained a buffer consisting of 100 mM KCl, 10 mM MnCl 2 , and 25 mM Na ϩ HEPES, pH 7.4. Steady-state emission spectra were recorded at low speed with ex ϭ 350 nm ( em ϭ 370-500 nm) and ex ϭ 280 nm ( em ϭ 300-500 nm) with 1 M MANT-GTP or 1 M MANT-ATP in the absence and presence of 5 M VC1 plus 25 M IIC2 without and with 100 M MP-FSK. Fluorescence recordings were analyzed with the spectrum package of the Cary Eclipse software (Varian, Walnut Creek, CA). Baseline fluorescence (buffer alone) was subtracted. Figure 1 shows superimposed original fluorescence recordings. Similar results were obtained in four independent experiments using two different batches of VC1 and IIC2.
Crystallization, Structure Determination, and Model Refinement for AC Complexes with TNP-ATP and MANT-ATP. A mixture of individually purified recombinant VC1, IIC2, and trypsin-AC Inhibition by Purine and Pyrimidine Nucleotides treated G␣ s ⅐GTP␥S (1.5:1:1) was passed through tandemly arranged Superdex 75 and 200 gel filtration columns (GE Healthcare, Little Chalfont, Buckinghamshire, UK) in the presence of excess MP-FSK and GTP␥S. Fractions containing the heterotrimeric complex were collected and concentrated to 8 mg/ml in a buffer of 20 mM Na ϩ HEPES, pH 8.0, 2 mM EDTA, 2 mM MgCl 2 , 2 mM dithiothreitol, 100 mM NaCl, 25 M MP-FSK, and 10 M GTP␥S for crystallization. Adenylyl cyclase protein complex crystals were grown, harvested, and cryoprotected under the conditions described previously (Tesmer et al., 2002; Mou et al., 2005) . Before cryoprotection, crystals were soaked in reservoir solution containing 2 mM TNP-ATP or 2 mM MANT-ATP with 3 mM MnCl 2 for 2 to 4 h at room temperature and then harvested in cryoprotectant. Cryoprotected crystals were mounted in 0.1-to 0.2-mm loops and stored in liquid nitrogen.
Diffraction data sets were collected by the oscillation method at the Advanced Light Source (ALS) 8.2.1 beamline at Berkeley, CA with an incident beam wavelength of 1.0781Å, and the images were processed with the HKL2000 package (Otwinowski and Minor, 1997) . As a result of anisotropy, data with l index Ͼ20 for crystals of the TNP-ATP⅐Mn 2ϩ complex and l index Ͼ18 for crystals of the MANT-ATP⅐Mn 2ϩ complex were excluded from the data set. Crystals of the protein complex with MANT-ATP⅐Mn 2ϩ or TNP-ATP⅐Mn 2ϩ were nearly isomorphous with those of the VC1:IIC2⅐FSK: G␣ s ⅐GTP␥S complex (Tesmer et al., 1997) . Coordinates of the latter complex with MANT-GTP (Protein Data Bank code 1TL7) were used as the initial phasing model. The inhibitors and metal ions in the structures were located in a SIGMA-A weighted Έ Fo Έ Ϫ Έ Fc Έ difference omit map computed with phases from the refined model. Atomic positions and thermal parameters were refined by successive rounds of rigid body, simulated annealing, Powell minimization, and B factor refinement using the CNS 1.1 program suite (Brunger et al., 1998) . The model was iteratively improved by manual refitting into weighted 2 Έ Fo Έ Ϫ Έ Fc Έ maps using the computer graphics program O (Jones et al., 1991) , and subsequent cycles of refinement using CNS.
Coordinates for the TNP-ATP⅐Mn 2ϩ and MANT-ATP⅐Mn 2ϩ structures have been deposited in the Protein Data Bank with the codes 2GVD and 2GVZ, respectively. Singular Value Decomposition (SVD) Calculation and Error Analysis. For each member, i, of a set of twenty AC inhibitors, inhibitory potency, K i , was modeled as the sum of the contributions, i (j), of the two or three equally weighted chemical functional groups of which the inhibitor is composed:
where f j is equal to 1/2 or 1/3 for nucleotide inhibitors that comprise two or three functional moieties (j), respectively. All of the nucleotide inhibitors in the data set contain at least two independent components: a nucleoside moiety and a (poly)phosphate group. A 2Ј(3Ј)-Oribosyl substituent constitutes the third functional component that is present in most of the inhibitors in the data set. The i (j) comprise a set of 13 independent variables, which, in combinations of two or three, describe all members of the experimental data set. Five components, i (j), correspond to contributions from possible phosphate functional groups (mono-, di-, tri-phosphate, ␥-[thio]triphosphate, and (␤␥-imidino)triphosphate), six to nucleoside moieties (adenine, guanine, cytidine, uracil, hypoxanthine, and xanthine nucleoside), and two contributions to the 2Ј(3Ј)-O-ribosyl substituents, MANT and TNP. K i values for 20 inhibitors were experimentally determined in this study, or in published work (Table S1 ). The experimental data set of inhibition constants for 20 compounds was modeled in a system of 20 equations (eq. 1) in 2 to 3 of 13 variables, as follows:
Least-squares fit of the 13 i values to eq. 2 was carried out by singular value decomposition (SVD) (Press et al., 1992; Gray, 1997) . The data matrix was decomposed as the product of two orthonormal matrices and a pseudo-diagonal matrix. Equation 1 was recast as
, where K i (i), i ϭ 1 to 20, are the measured AC inhibition K i values for the 20 dependent inhibitors, the i (j) are the values of two or three of the possible 13 independent components that constitute compound (i), and the elements N ij are set to 1 if the jth independent component is present in the ith inhibitor and to 0 otherwise. SVD of N ij / i gives USV t ( i is the standard deviation of log[K i (i)] derived from nonlinear regression of log[⌲ i (i)] versus AC activity. It is noted that 20% of log[K i ] value was used as standard deviation for those inhibitors from Gille et al. (2004) . S is a diagonal jϫ j matrix of singular values for the set of independent components. The columns of the 20 ϫ j matrix U are orthonormal basis vectors that together with the significant values of S and the corresponding rows of the jϫ j matrix V t (where t denotes the transpose) provide the best least-squares approximation to the original matrix N ij / i . The (Press et al., 1992; Mou et al., 1999) . Finally, substituting these values in eq. 2 gave the best-fit independent component values for the 13 values of log[ i (j)], from which calculated K i (i) were obtained. These best-fit values could be compared with the experimentally determined K i (i) values. A statistical test of the fit of the models is given by the probability Q (Press et al., 1992) that the 2 value (where
2 ) from the fit to the data would be larger by chance. A larger value of Q indicates a better fit. Values of Q Ͼ 0.1 are adequate and may be acceptable above 0.001 (Press et al., 1992) .
Results
Inhibition of VC1:IIC2 by MANT Nucleotides and TNP Nucleotides. As was reported previously (Gille et al., 2004; Mou et al., 2005) , MANT-ATP and MANT-GTP inhibited the catalytic activity of VC1:IIC2 that was maximally stimulated by FSK, GTP␥S-bound G␣ s and Mn 2ϩ , with K i values in the 10 nM range (Table 1) . However, when the linker between the MANT group and the ribosyl moiety was elongated to an aminoethyl-carbamoyl group, inhibitor potency at the fully activated VC1:IIC2 enzyme decreased approximately 500-fold. Translocation of the MANT group from the 2Ј,3Ј-O-ribosyl position to the N6-position (6-MANT-ATP) or N8 position (MABA-ATP and MAHA-ATP) of the adenine ring was also poorly tolerated in terms of potency. Extension of the linker between the adenine ring and MANT from butyl to hexyl (MABA-ATP3MAHA-ATP) was particularly detrimental to inhibitor potency.
TNP nucleotide triphosphates are moderately potent inhibitors of VC1:IIC2, with K i values in the 100 nM range (Table 1) . Like 2Ј,3Ј-MANT nucleotides, 2Ј,3Ј-TNP nucleotides are fluorescent (Hiratsuka, 2003) . However, a major difference between MANT-and TNP nucleotides is that the TNP group is linked to both the 2Ј-and 3Ј-O-ribosyl atoms, preventing isomerization of the fluorophore and yielding a more defined but also more rigid molecule. Compared with MANT-ATP and MANT-GTP, TNP-ATP and TNP-GTP were approximately 7-fold less potent inhibitors of the fully activated VC1:IIC2 enzyme. Nonetheless, given their rigid structures, the potency of TNP-ATP and TNP-GTP was still very remarkable. In fact, the affinity of TNP-ATP and TNP-GTP for VC1:IIC2 is among the highest reported for targets of TNP nucleotides (Hiratsuka, 2003) . It was also very remarkable that the pyrimidine nucleotide TNP-UTP exhibited nearly the same affinity for VC1:IIC2 as the purine nucleotides TNP-ATP and TNP-GTP. Exchange of uracil for cytidine, another pyrimidine base, reduced inhibitor potency 3-fold; nonetheless, the affinity of TNP-CTP for VC1:IIC2 surpassed that of TNP nucleotides for most other known target proteins (Hiratsuka, 2003) . Elimination of the ␥-phosphate in TNP-ATP, yielding TNP-ADP, reduced inhibitoraffinity 16-fold, and the elimination of the ␤-phosphate, yielding TNP-AMP, reduced inhibitor-affinity by an additional 13-fold. For TNP-GTP, the effect of elimination of the ␥-phosphate was even more pronounced, with a 100-fold reduction in affinity.
We also determined the potencies of nucleotides at inhibiting the submaximally activated VC1:IIC2 enzyme (i.e., the enzyme in the presence of FSK and Mn 2ϩ but in the absence of activated G␣ s . Under these conditions, the potencies of MANT-GTP, MANT-ATP, and TNP-GTP were up to 10-fold lower, whereas the affinity of TNP-CTP was 3-fold higher. For the other nucleotides, the omission of activated G␣ s had little effect on inhibitor potency.
Fluorescence Analysis of the Interaction of MANT-GTP and MANT-ATP with VC1:IIC2. In a previous study, we showed that the MANT group of MANT-GTP intercalates into a hydrophobic pocket between VC1 and IIC2, giving rise to increased nucleotide fluorescence at ex ϭ 350 nm . This fluorescence was further enhanced by the addition of the AC activator MP-FSK. Moreover, we observed FRET from Trp1020 of IIC2 to the MANT-group of MANT-GTP at ex ϭ 280 nm.
At ex ϭ 350 nm, both MANT-GTP and MANT-ATP were excited to emit light with a maximum at em ϭ 450 nm (Fig.  1, B and D) . Upon addition of VC1:IIC2, the fluorescence of both MANT-GTP and MANT-ATP was increased, but the fluorescence increase with MANT-GTP was larger than with MANT-ATP. Addition of MP-FSK to samples further enhanced fluorescence; again, the fluorescence increase with MANT-GTP was larger than with MANT-ATP. Moreover, we noted that with MANT-GTP, the emission peak was shifted to shorter wavelengths than with MANT-ATP, indicating that the MANT group in MANT-GTP resided in a more hydrophobic environment than the MANT group of MANT-ATP .
As reported earlier , we observed FRET from Trp1020 of IIC2 to the MANT-group of MANT-GTP at ex ϭ 280 nm. At this wavelength, both MANT-GTP and MANT-ATP alone in solution showed only minimal fluorescence (Fig. 1, A and C) . Upon addition of VC1:IIC2, large fluorescence signals with a peak at ex ϭ 350 nm were observed, corresponding to the endogenous tryptophan fluorescence of the protein. It should be noted that the shape of the emission spectra at ex ϭ 280 nm was different for MANT-GTP and MANT-ATP. In particular, the spectrum in the presence of MANT-ATP was steeper than in the presence of MANT-GTP (Fig. 1 , compare green traces with the black (Fig. 1) , prompted us to compare the X-ray crystal structures of VC1:IIC2 bound to MANT-ATP with that of the complex of MANT-GTP, which was reported earlier . The remarkably high potencies of TNP nucleotides at inhibiting VC1:IIC2 (Table 1 ) led us to determine the X-ray crystal structure of VC1:IIC2 bound to TNP-ATP as well. Structures of G␣ s ⅐GTP␥S⅐VC1:IIC2⅐MP-FSK protein complexes with TNP-ATP⅐Mn 2ϩ and MANTATP⅐Mn 2ϩ were determined at 2.9-and 3.3-Å resolution, respectively. The 2 Έ F oΈ Ϫ Έ F cΈ difference maps computed for crystals soaked in Mn 2ϩ and TNP-ATP or MANT-ATP showed clearly interpretable electron density around the substrate-binding site (Fig. 2) . Table 2 provides a summary of the crystallographic data collection and refinement statistics. The purine riboside and triphosphate moieties of both inhibitors occupy the same subsites observed for the corresponding groups of other ATP analogs (Tesmer et al., 1997 (Tesmer et al., , 2000 , and their 2Ј,3Ј-ribosyl substituents bind to the previously recognized MANT binding pocket at the C1:C2 interface . Difference Έ F oΈ Ϫ Έ F cΈ electron density for metal ions at the A and B sites is observed in both structures and is stronger than that in complexes in which only Mg 2ϩ is present (data not shown), indicating that Mn 2ϩ replaced Mg 2ϩ at both sites. The two metal ions coordinate the 5Ј-triphosphates of 2Ј,3Ј-ribosyl-substituted ATP, and their protein ligands occupy roughly the same positions seen in complexes with MANT-GTP or un-/noncompetitive AC inhibitors (so-called P-site inhibitors) (Dessauer et al., 1999) . However, the average temperature factors (B-factors) of TNP-ATP⅐Mn 2ϩ and MANT-ATP⅐Mn 2ϩ are 71 and 90 Å 2 and higher than those of the other ligands in the structure, MP-FSK and GTP␥S, which are 34 and 41 Å 2 , respectively. Therefore, we infer that the ATP analogs are less well ordered than the latter two ligands. Given the diffraction limits of the crystals of the two complexes, it is also possible that the high B-values reflect only partial occupancy of the catalytic site of C1:C2 by TNP-ATP and MANT-ATP. Because of the modest resolution of the data, combined with high Bfactors of the ATP analogs, hydrogen bond interactions in the MANT-ATP⅐Mn 2ϩ -bound complex cannot be unambiguously assigned.
We reported previously that the MANT fluorophore of MANT-GTP hampered the movement of the ␤1-␣1-␣2 loop of C1 and the ␣4Ј-␤5Ј and ␤7Ј-␤8Ј loops of C2 from the inactive (open) conformation to the active (closed) conformation (Fig. 3, A and D) . The TNP moiety of TNP-ATP ( Figs. 2A and 3B ) and the MANT substituent of MANT-ATP (Figs. 2B and 3C) occupy the same binding pocket at the C1:C2 interface and similarly prevent full domain closure. The overall pairwise root-mean-square deviations between corresponding C␣ atoms of TNP-ATP⅐Mn 2ϩ , MANTATP⅐Mn 2ϩ , and MANT-GTP⅐Mn 2ϩ complexes are less than 0.6 Å, suggesting that the global conformational differences among these inhibitor-bound complexes are small. However, relative to complexes with potent inhibitors, such as ␤-L-2Ј,3Ј-dideoxy-5Ј-ATP, the catalytic site, particularly the purine binding subsite, is slightly enlarged as a result of the intercalation of the MANT or TNP substituent between the C1 and C2 domains.
The conformations of TNP-ATP and MANT-ATP and their interactions with VC1:IIC2 residues in the substrate-binding site are illustrated in Fig. 3 , B and C, respectively. The structure of the MANT-GTP⅐Mn 2ϩ complex is also shown in Fig. 3D for comparison. The positions and orientations of 3Ј-MANT or 2Ј,3Ј-TNP substituents of ATP are similar to that of 3Ј-MANT of GTP in the binding groove between ␤1-␣1-␣2 of VC1 and ␣4Ј-␤5Ј of IIC2. The MANT groups of both MANT-ATP and MANT-GTP are in van der Waals contact with VC1 and IIC2 but do not form hydrogen bonds with neighboring protein residues. This binding pocket contains a group of conserved nonpolar residues including Trp1020 of 
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IIC2 and two residues, Ala409 of VC1 and Ile1006 of IIC2, that are not conserved among the type I-VIII mAC isoforms . Substitution of Ala409 of VC1 with proline and/or Ile1006 of IIC2 with valine reduces the inhibitory potency of MANT-GTP to mAC by 2-to 10-fold, indicating that these nonconserved residues in the MANT binding pocket influence the affinity of mAC for inhibitors with 3Ј-MANT substituents. In the TNP-ATP⅐Mn 2ϩ complex, the TNP substituent of ATP is bound to the same pocket that is occupied by the MANT group of the inhibitors described above. The two polar NH 2 groups of TNP seem to form hydrogen bonds with the carboximido NH 2 groups of Asn1022 and Asn1025 of IIC2 and the backbone oxygen of Ala409 of VC1 (Figs. 3B and 4E ). These hydrogen bonds are presumed to stabilize the TNP ring in the VC1:IIC2 substrate-binding site.
The overall placement of the purine ring and 5Ј-triphosphate of TNP-ATP in the active site is similar to that of MANT-ATP (Figs. 2 and 3) . Lys1029 from the ␣4 helix of IIC2 interacts with the nucleotide phosphates of analogs such as ␤-L-2Ј,3Ј-dideoxy-5Ј-ATP, which bind to and promote a fully closed conformation of the catalytic domain in which the C1 and C2 domains are in close opposition . This interaction cannot occur in the TNP-and MANT nucleotides because their 2Ј,3Ј-ribosyl substituents act as a wedge, preventing formation of the closed, active conformation (Fig. 3A) .
The three derivatives differ greatly in the coordination of their poly-phosphate chains with neighboring protein residues and metal ions. In particular, the positions occupied by the ␤-and ␥-phosphates of TNP-ATP are very close to those taken by the corresponding phosphates of ␤-L-2Ј,3Ј-dideoxy-5Ј-ATP and adenosine 5Ј-[␣-thio]triphosphate but correspond to the binding sites of the ␣-and ␤-phosphates of MANT-ATP and MANT-GTP. As a result, Lys484 of VC1 can interact with the ␥-phosphate of TNP-ATP (as in the complex with ␤-L-2Ј,3Ј-dideoxy-5Ј-ATP) but not with the ␥-phosphate of MANT-GTP (Fig. 3, B-D) . Lys1065 from ␤7Ј-␤8Ј of IIC2 interacts with a ␤-phosphate oxygen and the ␣-␤ bridging oxygen of TNP-ATP. The same interaction is observed with the corresponding atoms in the MANT-GTP complex (Fig. 3,  B and D) . Metal B is essential for stabilizing the ligand through an octahedral coordination with the oxygen atoms of two phosphates and three VC1 residues (Asp396, Ile397, and Asp440) in both TNP-ATP⅐Mn 2ϩ and MANT-GTP⅐Mn 2ϩ complexes (Fig. 2) . Conversely, in the TNP-ATP⅐Mn 2ϩ complex, metal A is coordinated by the two aspartate residues (Asp396 and Asp440) from VC1, but not with the ␣-or ␤-phosphates as observed in the MANT-GTP⅐Mn 2ϩ complex ( Figs. 2A and  3D ). It should be noted that both TNP-ATP⅐ Mn 2ϩ and MANT-ATP⅐Mn 2ϩ complexes were cocrystallized with MP-FSK rather than FSK. The 7-acetyl-7-[O-(N-methylpiperazino)-␥-butyryl] moiety of this ligand is bound closely to, but makes no direct contact with, the metal-A site (Figs. 2 and 3 ) in either structure.
The MANT and TNP nucleotide complexes show that the substrate-binding site of mAC is able to accommodate different purine substituents. It is remarkable that the purine moieties of TNP-ATP and MANT-ATP are bound to the same mAC subsite in completely different orientations (Fig. 4, A  and D) . The base of TNP-ATP adopts an anti conformation ( ϭ 234°) with respect to the ribose ring as observed for the guanine ring of MANT-GTP, but MANT-ATP adopts the syn orientation ( ϭ 64°), which is similar to that observed for other ATP analogs . Whereas the N6 and N7 atoms in the adenine ring of TNP-ATP form hydrogen bonds to Ser1028 of IIC2 (Fig. 3B) , there are no apparent hydrogen bond interactions between the adenine ring of MANT-ATP and protein residues. The adenine moiety of MANT-ATP is observed at a position that is intermediate between the purine rings of MANT-GTP and TNP-ATP in the base-binding pocket (Fig. 4, A and D) . Therefore, the potency for AC inhibitors containing 2Ј,3Ј-ribosyl substituents is not greatly determined by their nucleoside base, as is discussed below.
Discussion
The three independent X-ray crystal structures of VC1: IIC2 in complex with 2Ј,3Ј-ribose-substituted nucleotide AC inhibitors reported here and previously reveal common features that we propose to be essential for their potency. A general tripartite pharmacophore model for catalytic site-targeted mAC inhibitors can be derived from the structural data and is supported by a systematic enzymatic analysis of natural and modified purine and pyrimidine nucleotides (Gille et al., 2004 Mou et al., 2005) (Fig. 4 , B and C, and Table 1 ). The inhibitor site, which overlaps the binding site for the substrate ATP, contains a deep hydrophobic pocket for a 2Ј,3Ј ribose substituent, a polar phosphate-binding groove adjacent to the catalytic Mn 2ϩ -binding site, and a spacious base-binding pocket (Fig. 4A) . Superposition of the three potent inhibitors MANT-GTP, TNP-ATP, and MANT-ATP in the AC substrate binding site (Fig. 4) shows that the ribose substituents and triphosphate a Numbers in parentheses refer to data in the highest resolution shell.
where I(h) is the mean intensity after rejections.
c Because of anisotropy, data with l index greater than 20 were omitted from refinement.
and F c (h) are observed and computed structure factors; no I/ cutoff was used during refinement.
e Five percent of the complete data set was excluded from refinement to calculate R free .
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group (in coordination with two metal ions) are nearly aligned, but the base rings of these molecules are not.
Complementarity between the ribose-substituent and its binding pocket is essential for high-affinity binding. We previously showed that incorporation of a MANT group at the 3Ј-position of inosine 5Ј-[␥-thio]triphosphate increased inhibitory potency 60-fold (Gille et al., 2004) . However, potency is decreased up to 40-fold relative to inosine 5Ј-[␥-thio]triphosphate when the ribose is substituted with a larger bulky BODIPY group, demonstrating the size-selectivity of the binding site for the ribose substituent of the inhibitor (Gille et al., 2004; Mou et al., 2005) . In the present study, we show that substitution of UTP or CTP with 2Ј,3Ј-TNP increases the affinity of these pyrimidine nucleotides by up to 20,000-fold (Table 1) . Substitution of ATP with 2Ј,3Ј-aminoethyl-carbamoyl-MANT instead of MANT decreases potency up to 500-fold (Table 1) , again confirming the sizeselectivity of the pocket that accommodates the ribose substituent.
Several nonpolar residues conserved among mAC isoforms, including Trp1020 of IIC2, create a hydrophobic surface in the binding pocket for the ribose substituent . The increase in MANT fluorescence upon binding of MANT-GTP and MANT-ATP, or of FRET from MANT to Trp1020 (Fig. 1) , is consistent with the interaction of the fluorophore with this hydrophobic pocket. Formation of hydrogen bonds between the NO 2 substituents of the trinitrophenyl group and polar groups in the binding site is probably crucial for the moderately high inhibitory potency of TNPsubstituted nucleotides (Fig. 4E) .
The nucleotide triphosphates that coordinate the two metal cofactors also provide substantial binding energy for interaction with VC1:IIC2. During catalysis, both metal ions play critical roles in ATP binding by coordinating the 3Ј-hydroxyl and 5Ј-triphosphate of ATP and neighboring protein residues around the catalytic core (Tesmer et al., 2000) . Metal-B coordinates with the ␥-and/or ␤-phosphate(s) of ATP analogs in the C1:C2 binding site (Tesmer et al., , 2000 Mou et al., 2005) (Fig. 2B) . Elimination of the ␥-phosphate or ␤-and ␥-phosphates of TNP-ATP reduce its affinity for VC1: IIC2 by approximately 20-and 200-fold, respectively ( Table  1 ). The ␥-phosphate is important for high binding affinity of TNP-GTP as well. The ␥-phosphates of MANT-ATP and MANT-GTP also contribute at least 4-fold to their potency relative to the corresponding nucleotide diphosphates (Gille et al., 2004) . The crystallographic data unequivocally dem- Fig. 3 . Views of crystal structures of G␣ s ⅐ VC1⅐IIC2 in complex with substrate analogs. A, a wide-range view of complex of G␣ s -activated mAC with TNP-ATP and two Mn 2ϩ ions in the catalytic site. VC1, IIC2, and G␣ s are shown in mauve, tan, and gray, respectively. The ␣2 (switch II) helix of G␣ s is shown in red. MP-FSK, TNP-ATP and two metal ions occupy the interdomain cleft between the C1 and C2 domains. Secondary structure elements are labeled as defined previously (Tesmer et al., 1997) . Detailed views of the substrate-binding site of VC1⅐IIC2 showing TNP-ATP (B), MANT-ATP (C), and MANT-GTP (PDB 1TL7) (D) and two Mn 2ϩ ions, respectively. MP-FSK and nucleotide inhibitors are drawn as stick models; carbon atoms are gray, nitrogen is blue, oxygen is red, and phosphorus is green; the two Mn 2ϩ ions are shown as metallic orange spheres. Single-letter amino acid abbreviations are presented with position numbers, and protein residues are shown as stick models. The ribose substituents of inhibitor molecules are positioned between the ␣4 helix of IIC2 and ␣1-␣2 helices of VC1. Interactions are shown among protein residues, inhibitors, and two metal ions in the VC1⅐IIC2 substrate-binding site. The gray dashed lines depict the hydrogen bonds between inhibitor molecules and protein residues, and coordination of the metal ions at sites A and B. Because of the high thermal parameters of the nucleotide (see text), hydrogen bond distances are approximate.
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onstrate that the Mn 2ϩ ion in the A-site coordinates with the ␣-phosphate of MANT-substituted nucleotides, but not with that of TNP-ATP ( Fig. 2A) . Therefore, at least one metal ion at B site is essential to coordinate and stabilize the polyphosphate chain in the binding groove.
The capacious subsite that accommodates the purine bases of MANT/TNP nucleotide inhibitors has little specificity; inhibitors with guanine, hypoxanthine and adenine bases have similar potency (Table 1) (Gille et al., 2004; Mou et al., 2005) . Because the glycosidic angle has great rotational freedom, the orientation of the base is not restrained in these inhibitors. The structures of MANT/TNP nucleotide-VC1:IIC2 complexes show that the base rings of the inhibitor can be stabilized by different hydrogen bonding arrangements with the IIC2 purine-binding site depending on their orientation. In particular, the guanine ring of MANT-GTP and the adenine ring of P-site inhibitors are in opposite orientations, but maintain similar hydrogen bond pairs with Lys938, Asp1018, and Ile1019 from IIC2. The adenine ring of TNP-ATP adopts yet a different orientation in the binding pocket and forms a hydrogen bond with Ser1028 of IIC2 (Fig. 4D) . However, in the context of other structural variations in the above three inhibitors, hydrogen bonds to the base seem to contribute little to interaction strength. The absence of base specificity for MANT or TNP-substituted purine nucleotides extends as well to their pyrimidine analogs. The inhibitory potencies of TNP-substituted pyrimidine nucleotides are at least comparable with, or even surpass those of, TNP-substituted purine nucleotides (Table 1) . Nonetheless, bulky substitutions at various nitrogen atoms of the purine ring, such as those in 6-MANT-ATP, MABA-ATP, and MAHA-ATP, are not tolerated ( Table 1 ), indicating that conformational flexibility of the purine-binding site of VC1:IIC2 is limited.
We have used SVD to quantitatively compare the contributions to inhibitory potency from the independent functional groups in a set of 2Ј,3Ј-ribose-substituted nucleotide AC inhibitors. A relationship (eq. 1) was developed to express the K i values of these compounds in terms of contributions from two to three chemical components corresponding to the base, phosphate, and 2Ј(3Ј)-O-ribosyl substituent. The data set of 20 inhibitors (Table 3 ) encompasses 13 variations of these three components (see Materials and Methods). SVD of the matrix of twenty equations corresponding to the inhibitor set (eq. 2) provides the least-squares fit of the observed K i values to the thirteen independent affinity components i that encompass the chemical variation among inhibitors. The i values can be used to reconstitute computed K i values that are comparable in magnitude with the observed set (Table 3; see Table 1 in the supplementary material). This analysis shows that the 2Ј(3Ј)-O-ribosyl substituent (MANT or NP) contributes 20-fold more to inhibitory potency than the phosphate group and nearly 1000-fold more than the base, as illustrated in the schematic shown in Fig. 4C . Although the data allowing comparison of the effects of MANT-and TNP- Table 3 . The latter were derived from SVD of the set of relationships given by eq. 1. The xanthine and monophosphate nucleotides were excluded from the averaging i values for their apparently unfavorable contributions to the respective pharmacophore. D, a detailed schematic of base centers in the VC1:IIC2 purine-binding pocket. Hydrogen bonds between base (adenine group of TNP-ATP and guanine group of MANT-GTP) and neighboring IIC2 protein residues are shown in dashed lines. E, base substituent centers of inhibitors in the VC1:IIC2 substrate-binding site. Only the 2,4,6-trinitrophenyl substituent of TNP-ATP and the 2Ј-ribosyl OH of MANT-GTP form hydrogen bonds with VC1 and IIC2 protein residues. 
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substitution of nucleotide di-and triphosphates are limited to adenine and guanine nucleotides (Table 1 of this study and  Table 1 of Gille et al., 2004) , it is evident that MANT substitution contributes more to potency than derivatization by TNP (Table 3) .
Introduction of a bulky, aromatic group at the ribose 2Ј and 3Ј positions of ATP generates a class of mAC inhibitors that are resistant to hydrolysis and use a subsite at the interface of the C1 and C2 domains that is not present in the catalytically active conformation of the enzyme. The structures of complexes formed with such inhibitors indicate that the base-binding site is slightly enlarged, perhaps as a result of local distortions induced by binding of the MANT or TNP ribose substituent. Therefore, the specificity of base binding site for purines is relaxed relative to that of the active conformation of the enzyme, and specific interactions between the base and the base binding site have little influence on affinity for the inhibitor. For the MANT-and TNP-substituted nucleotides, binding energy not realized at the base binding site is recovered from interactions with the ribose substituent. Structures of a variety of C1:C2 complexes with ATP analogs and P-site inhibitors show that there is considerable variation in the mode of interaction between VC1:IIC2 and 5Ј-or 3Ј phosphate groups and pyrophosphate, although similar patterns of metal cation and hydrogen bond recognition are observed in all complexes (Tesmer et al., 2000) . The MANT/TNP nucleotide inhibitors take advantage of the plasticity of the phosphate binding site in forming interactions that optimize interactions at all subsites. Because mAC is deformable at the interface between its catalytic domains, the enzyme exhibits broad specificity for interaction with purine and pyrimidine nucleotides. MANT/TNP nucleotide inhibitors represent a novel class of potent mAC inhibitors in which relatively nonspecific yet energetically productive ionic van der Waals and hydrogen bonding interactions at three distinct subsites contribute to binding affinities in the 10 to 100 nM range. These compounds may be therefore viewed as lead compounds for the development of mAC isoform-specific, potent, and bioavailable inhibitors.
